Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $74.00 to $83.00. They now have an "overweight" rating on the stock.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed To Present at November 2024 Investor Conferences
Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $105.00 price target on the stock, up previously from $100.00.
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates [Yahoo! Finance]